Recent advances in the treatment of peritoneal metastasis from gastric cancer

Keizo Taniguchi, Yutaka Yonemura, Haruaki Ishibashi, Akiyoshi Mizumoto, Satoshi Wakama, F Cocolini, Hsin-Hsien Yu

Research output: Contribution to journalArticlepeer-review


Background:Peritoneal metastasis (PM) from gastric cancer (GC) was once considered a lethal disease. After the late 1990s, the therapeutic goal changed from palliative to curative intent because of a development a comprehensive treatment combining cytoreductive surgery (CRS) and perioperative chemotherapy.

Methods: Recent advances in the treatment of PM from GC reported in 18 studies including 2327 patients were reviewed.

Results: In patients with PM, systemic chemotherapy alone had a limited and non-curative effect. In contrast, radical gastrectomy plus neoadjuvant intraperitoneal/systemic chemotherapy (NIPS), early postoperative intraperitoneal chemotherapy (EPIC), or postoperative S1 treatment was shown to improve the survival of patients with cytology-positive (Cy1) peritoneal lavage fluid without macroscopic PM (P0) (P0Cy1). After 5 years, 23 among 154 patients were disease free. For the treatment of patients with macroscopic PM (P1), exploratory laparotomy to determine the peritoneal cancer index (PCI) and neoadjuvant laparoscopic hyperthermic intraperitoneal perfusion (LHIPEC) were performed. The combination of NIPS and LHIPEC was effective in patients with P1, but NIPS or LHIPEC alone were ineffective and all patients receiving one or the other died. In contrast, the 5-year survival rate after cytoreductive surgery (CRS)+HIPEC ranged from 6% to 13%, and 18 among 284 patients were disease free at 5 years.

Conclusions: AlthoughCRS and NIPS have an important role in treatment of PM from GC, complete cytoreduction by gastrectomy and peritonectomy after NIPS combined with intraoperative HIPEC, EPIC, and late postoperative chemotherapy may cure the patients with P0Cy1 or P1 disease.
Original languageUndefined/Unknown
Pages (from-to)1-6
Number of pages6
JournalCancer Rep Rev.
Issue number2
Publication statusPublished - 2018
Externally publishedYes

Cite this